{
  "resourceType": "ValueSet",
  "id": "febrileNeutropeniaRisk-ValueSet",
  "meta": {
    "lastUpdated": "2017-11-02T17:15:45.045+00:00"
  },
  "url": "http://ots.nccn.org/fhir/ValueSet/febrileNeutropeniaRisk-ValueSet",
  "name": "febrileNeutropeniaRisk-ValueSet",
  "title": "febrileNeutropeniaRisk-ValueSet",
  "status": "active",
  "date": "2017-10-24T14:31:20.729+00:00",
  "publisher": "National Comprehensive Cancer Network, Inc.",
  "description": "The risk of febrile neutropenia posed by this regimen.",
  "purpose": "Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that can result in hospitalization and the need for IV antibiotics. FN can also result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. It is thus important to identify the risk for developing FN so that patients can receive optimal chemotherapy while their risk for FN is appropriately managed.",
  "compose": {
    "include": [
      {
        "system": "http://ots.nccn.org/fhir/CodeSystem/febrileNeutropeniaRisk-CodeSystem"
      }
    ]
  }
}